metricas
covid
Buscar en
Clínica e Investigación en Arteriosclerosis
Toda la web
Inicio Clínica e Investigación en Arteriosclerosis Análisis de la actividad paraoxonasa (PON1) y de los polimorfismos PON1 192 y P...
Información de la revista
Vol. 19. Núm. 6.
Páginas 287-292 (noviembre 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 19. Núm. 6.
Páginas 287-292 (noviembre 2007)
Acceso a texto completo
Análisis de la actividad paraoxonasa (PON1) y de los polimorfismos PON1 192 y PON1 55 en la población prepuberal del Estudio Cuatro Provincias
Serum paraoxonase activity and pon1 192 and pon1 55 polymorphisms in prepuberal children. the four provinces study
Visitas
5829
Carmen Garcésa,
Autor para correspondencia
cgarces@fjd.es

Correspondencia: Dra. C. Garcés. Unidad de Lípidos. Fundación Jiménez Díaz. Avda. Reyes Católicos 2, 28040 Madrid. España. cgarces@fjd.es
, Laura López-Simóna, Rafael Rubioa, Mercedes Benaventea, Beatriz Canoa, Enrique Viturroa, Manuel de Oyaa, a
a Unidad de Lípidos. Fundación Jiménez Díaz. Universidad Autónoma. Madrid. España.
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Introducción

La paraoxonasa 1 (PON1) es una éster hidrolasa presente en las lipoproteínas de alta densidad (HDL), relacionada con la eliminación de componentes oxidados de las lipoproteínas de baja densidad (LDL) y por ello con el riesgo cardiovascular. Nuestro estudio analiza la actividad PON1 y los polimorfismos 192 y 55 del gen PON1 en los niños de edad prepuberal integrantes del Estudio Cuatro Provincias.

Métodos

La población de estudio la constituyen 1.275 niños de 6 a 8 años. La actividad PON1 en suero se determinó mediante la hidrólisis de paraoxon. Los polimorfismos genéticos PON1 192Q/R y PON1 55M/L se analizaron mediante amplificación por reacción en cadena de la polimerasa (PCR) y posterior análisis de restricción.

Resultados

En nuestra población la frecuencia de los alelos PON192R y PON55M es del 30 y el 38%, respectivamente, sin diferencias significativas entre provincias. La actividad PON1 es más elevada en Orense y más baja en Murcia, tanto en la población total como para cada uno de los genotipos. En la provincial de Orense se observaron correlaciones significativas entre la actividad PON1 y los valores plasmáticos de colesterol total (CT), colesterol unido a HDL (cHDL) y apolipoproteína AI (apo AI). El análisis de regresión muestra que el polimorfismo PON1 192Q/R es el principal determinante de la actividad PON1 en nuestra población.

Conclusiones

La frecuencia de los polimorfismos PON192 y PON55 no difiere significativamente entre provincias. Sin embargo, a pesar de que el polimorfismo PON192 es el principal determinante de la actividad PON1, Orense presenta la actividad PON1 más alta y Murcia la más baja, lo que sugiere que ya a esta edad existen factores que regulan esa actividad dentro de cada genotipo.

Palabras clave:
Población infantil
Actividad paraoxonasa
Polimorfismos genéticos
Background

Paraoxonase (PON1) is an ester hydrolase related to the elimination of oxidized compounds of low-density lipoprotein (LDL) particles and therefore to cardiovascular risk. The aim of the present study was to analyze the relationship between serum PON1 activity and PON1 192 and 55 polymorphisms in the prepuberal children included in the Four Provinces Study.

Methods

The study population included 1,275 children aged 6 to 8 years old. Serum PON1 activity was measured by paraoxon hydrolysis. PON1 192Q/R and PON1 55M/L polymorphisms were analyzed by polymerase chain reaction and restriction analysis.

Results

In the population as a whole, the prevalence of the less common PON192R allele was 30% and that of the PON55M allele was 38%, without significant differences in the frequencies between provinces. PON1 activity was highest in Orense and lowest in Murcia, both in the group as a whole and within each genotype. In Orense, significant correlations between PON1 activity and plasma total cholesterol, high-density lipoprotein cholesterol and apolipoprotein AI levels were found. Regression analysis showed that the PON1 192Q/R polymorphism is the main determinant of PON1 activity in our population.

Conclusions

No significant differences between provinces in the frequencies of the PON192 and PON55 polymorphisms were found. However, although the PON192 polymorphism is the main determinant of PON1 activity, Orense showed the highest activity and Murcia the lowest for all the genotypes, suggesting that already at this age some factors are regulating PON1 activity for each genotype.

Keywords:
Children
Paraoxonase 1 activity
Genetic polymorphisms
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults. Evidence from intravascular ultrasound. Circulation. 2001; 103:2705-10.
[2]
Risk factors in early life as predictors of adult heart disease: The Bogalusa Heart Study. Am J Med Sci. 1989; 298:141-51.
[3]
Factores de riesgo cardiovascular en la edad infantil. Resultados globales del Estudio Cuatro Provincias. Rev Esp Cardiol. 2007; 60:517-24.
[4]
Factores metabólicos en población escolar asociados a la mortalidad cardiovascular en los adultos. Estudio Cuatro Provincias. Med Clín. 2002; 118:767-70.
[5]
Consistently high plasma HDL-C levels in children in Spain, a country with low cardiovascular mortality. Metabolism. 2004; 53:1045-7.
[6]
Colesterol-HDL y mortalidad cardiovascular en España. Rev Esp Cardiol. 1998; 51:988-90.
[7]
High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochem Biophys Acta. 1990; 1044:275-83.
[8]
The role of high density lipoprotein and lipid soluble anti-oxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem J. 1993; 294:829-34.
[9]
Midly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997; 99:2005-19.
[10]
Protection of low-density lipoprotein against oxidative modification by highdensity lipoprotein associated paraoxonase. Atherosclerosis. 1993; 104:129-35.
[11]
The Yin and Yan of oxidation in the development of the fatty streak. Arteriosc Thromb. 1996; 16:831-3.
[12]
Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation. 2000; 101:2510-7.
[13]
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993; 52:598-608.
[14]
Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet. 1999; 353:468-9.
[15]
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzime. J Clin Invest. 1997; 99:62-6.
[16]
Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem. 1986; 32:671-3.
[17]
Serum Paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999; 19:330-5.
[18]
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991; 86:193-9.
[19]
Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003; 107:2775-9.
[20]
Are Canadian Inuit at increased genetic risk for coronary heart disease?. J Mol Med. 1997; 75:364-70.
[21]
The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol. 1998; 18:1611-6.
[22]
The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 1996; 126:299-303.
[23]
The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993; 3:73-6.
[24]
Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem. 2003; 49:1491-7.
[25]
Are Activity and Concentration More Important Than Genotype?. Arterioscler Thromb Vasc Biol. 2001; 21:1451-7.
[26]
Serum Paraoxonase activity and its relationship to diabetic complications in patients with non-Insulin Dependent Diabetes Mellitus. Metabolism. 1998; 47:598-602.
[27]
Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet. 1991; 40:277-82.
[28]
Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece. Clin Chem Lab Med. 2006; 44:623-7.
[29]
Sumegová K, Nagyová Z, Waczulíková I, Îitnanová I, Duracková Z. Activity of paraoxonase 1 and lipid profile in healthy children. Physiol Res. 2006 Jun 22. Epub ahead of print.
[30]
Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol. 1996; 16:1243-9.
[31]
Genetics of paraoxonase. Ann Hum Genet. 1981; 45:323-30.
[32]
The paraoxonase- 1 codon 192 polymorphism is associated with fasting total cholesterol and LDL-cholesterol concentrations only in postmenopausal women. The REGICOR study. Clin Chem Lab Med. 2002; 40:677-83.
[33]
Different pattern of association of paraoxonase Gln192>Arg polymorphism with sporadic late-onset Alzheimer's disease and coronary artery disease. Neurosci Lett. 2003; 339:17-20.
[34]
Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol. 1996; 57:69-73.
[35]
A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 1997; 17:3565-9.
[36]
Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?. Free Rad Biol Med. 2004; 37:1317-23.
[37]
Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res. 2006; 47:515-20.
[38]
Genetic and environmental factors modulating the serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 2004; 107:435-47.
[39]
Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin INvest. 2007; 37:187-96.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos